What are the long term risks of skyrizi?

What side effects show up years after starting Skyrizi?
Long-term data from open-label extensions of the UltIMMa-1, UltIMMa-2, and IMMvent trials show that serious infections, including tuberculosis reactivation, remain the main concern after three to five years. Rates stayed below 2 events per 100 patient-years, and no new safety signals emerged beyond the first year [1].

How does Skyrizi affect cancer risk over time?
In the same extension studies, non-melanoma skin cancers and other malignancies occurred at rates similar to the general psoriasis population. No dose-dependent increase appeared with continued every-12-week dosing [1].

Can Skyrizi cause liver damage that appears late?
Liver enzyme elevations were infrequent and usually mild. In the extension cohorts, fewer than 1 % of patients developed sustained ALT or AST increases above three times the upper limit of normal, and no cases met Hy’s law criteria [1].

What happens to the immune system after stopping Skyrizi?
After drug withdrawal, psoriasis returns in most patients within six to nine months. No rebound worsening beyond baseline severity was recorded, and infection or malignancy rates did not spike during the off-treatment period [1].

When does Skyrizi’s patent protection end?
AbbVie’s U.S. composition-of-matter patent for risankizumab expires in 2034. Several companies have filed patent challenges; outcomes are still pending at the Patent Trial and Appeal Board [2].

[1] https://www.drugpatentwatch.com/drug/risankizumab
[2] https://www.drugpatentwatch.com/drug/risankizumab